Continuity Biosciences has filed a notice of an exempt offering of securities to raise $12 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Continuity Biosciences is raising up to $12,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Continuity Biosciences
Continuity Biosciences, LLC, is dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and ultra-long acting drug delivery. The company seeks to leverage the immense potential at the intersection of biopharmaceuticals and medical technologies, especially in creating combination products that can help realize the full potential of remarkable therapies. While our foundation is built on technologies licensed from Prof. Grattoni’s pioneering research at the Houston Methodist Hospital, we plan to continuously expand our technology portfolio to provide our partners with diverse options for their product presentation strategies.
To learn more about Continuity Biosciences, visit https://continuitybiosciences.com/
Continuity Biosciences Linkedin Page: https://www.linkedin.com/company/continuity-biosciences/
Contact:
Ramakrishna Venugopalan, Chief Executive Officer
919-480-3892
https://www.linkedin.com/in/ramakrishna-venugopalan-619b0b13/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
